Arcturus Therapeutics Stock Forecast
NASDAQ: ARCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ARCT analyst consensus
Consensus (13 analysts)
strong_buy
Avg. price target
$23.20+80.26%
- Strong buy 1
- Buy 10
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering Arcturus Therapeutics (2026-10-08), 11 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $23.20, with a high estimate of $41.00 and a low estimate of $9.00. The average target implies upside of 80.3% from the current price of $12.87.
The spread between the highest and lowest targets is 355.6%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ARCT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 8% |
| Buy | 10 | 77% |
| Hold | 2 | 15% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $9.00 | -30.07% |
| Average target | $23.20 | +80.26% |
| High target | $41.00 | +218.57% |